Status:
UNKNOWN
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborating Sponsors:
Tainan Hospital, Ministry of Health and Welfare
Conditions:
Autoimmune Diseases
Helicobacter Pylori Gastritis
Eligibility:
All Genders
20-90 years
Brief Summary
The study is aimed to investigate the different rates of pyloric/ pseudopyloric metaplasia or spasmolytic polypeptide-expressing metaplasia (SPEM) of corpus between autoimmune gastritis and H. pylori-...
Detailed Description
Autoimmune gastritis is not an uncommon disease among northern European ancestry, but its prevalence rates are unclear in other populations, including Taiwanese. A study showed that near 2% of persons...
Eligibility Criteria
Inclusion
- Patients who present with relevant symptoms or signs of upper gastrointestinal diseases, including, but not limited to the following: impaired gastric emptying, epigastric discomfort, postprandial bloating, early satiety, epigastric pain, acid regurgitation, dyspepsia, anemia, or vitamin B12 deficiency, or iron deficiency, are candidates to be enrolled to receive gastroscopy.
Exclusion
- The exclusion criteria are as follows including use of aspirin, non-steroidal anti-inflammatory drugs, or cyclooxygenase-2 selective inhibitors for more than 3 months, or diagnosis with upper gastrointestinal cancer including esophagus, stomach, duodenum, mucosa-associated lymphoid tissue lymphoma, other gastric lymphoma, or pancreas.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05238181
Start Date
January 1 2022
End Date
December 31 2024
Last Update
October 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cheng Kung University Hospital
Tainan, Taiwan, 704302